Stock screenerAll disclosures →
EDGAR →
MAZE
Conviction 50HealthcareScan · Mon, Aug 10, 2026MAZE$27.24-4.92%
ResistanceSupportVol 14Insider sell4
2
4
2
2
Vol MA14 335.04K
May 11May 28Jun 16Jul 6Jul 23Aug 10
Price27.24
Change-4.92%
Gap-1.71%
Rel volume1.78×
Avg volume369.45K
Avg $ vol10.35M
SMA 2028.08
SMA 5027.47
SMA 20034.54
Price vs 50-0.85%
Price vs 200-21.13%
MA stackbearish
50/200 cross—
Supertrenddown · 31.18
RSI (14)45
MACD hist-0.08
MACD cross—
Stoch %K / %D40 / 63
ADX (14)14
+DI / −DI18 / 24
RSI divergence—
MACD divergence—
ATR %+5.87%
ADR %5.42%
52w high51.84
52w low13.14
From 52w high-47.45%
Above 52w low+107.31%
New 52w highNo
SqueezeOn · 3d
Bollinger width11.28%
%B0.23
Donchian pos29.51%
Donchian high30.56
Donchian low25.85
AVWAP (52w high)29.85
vs AVWAP high-8.74%
AVWAP (52w low)31.86
vs AVWAP low-14.51%
OBV trendFlat
Chaikin MF (20)-0.06
Today vs 20d1.78×
Avg vol (14d)335.04K
Avg vol (20d)369.45K
Avg $ vol (20d)10.35M
Market cap1.51B
RS 3m (vs SPY)+6.79%
RS 6m (vs SPY)-48.93%
RS line new highNo
Trend template3/8
Technical rank15.1
1 week-0.33%
1 month-10.89%
3 months+4.65%
6 months-39.51%
1 year+104.50%
YTD-31.51%
P/E-11.50
P/B4.41
P/S9.00
P/FCF-13.37
EPS-3.05
Div yield—
ROE-38.37%
ROA-31.24%
Debt/Eq0.11
Current17.88
EV/EBITDA—
Gross margin—
Net margin-78.28%
Rev growth—
EPS growth-351.04%
Price target70.00
Target upside156.98%
Analyst ratingBuy
Institutional96.42%
Ent. value1.35B
Revenue20M
Net income-24.21M
Gross profit—
Free cash flow-112.73M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out55.35M
Employees141
ListedFri, Jan 31, 2025
Free float28.18M
Float %58.6%
Short interest5.53M
Days to cover8.5d
Short volume89.6%
Squeeze score96 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.45 vs −$0.43
Last surprise-4.7% miss
Setup gradeC
Conviction50 / 100
Pattern quality—
Tech rank15.1 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance31.52
Support24.68
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in MAZE
No recent disclosed trades by Congress in MAZE. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in MAZE · 3 buys · 7 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Coloma Jason V Chief Executive Officer · Common Stock · 2026-08-03 | Sell | 154 | $4K | 2026-08-03 | 2026-08-05 |
Coloma Jason V Chief Executive Officer · Common Stock · 2026-08-03 | Sell | 1.6K | $43K | 2026-08-03 | 2026-08-05 |
Coloma Jason V Chief Executive Officer · Common Stock · 2026-08-03 | Sell | 30.3K | $810K | 2026-08-03 | 2026-08-05 |
Coloma Jason V Chief Executive Officer · Common Stock · 2026-08-03 | Sell | 2.44K | $65K | 2026-08-03 | 2026-08-05 |
Coloma Jason V Chief Executive Officer · Common Stock · 2026-06-23 | Sell | 23.86K | $622K | 2026-06-23 | 2026-06-24 |
Coloma Jason V Chief Executive Officer · Common Stock · 2026-06-22 | Sell | 1.95K | $51K | 2026-06-22 | 2026-06-24 |
Coloma Jason V Chief Executive Officer · Common Stock · 2026-06-22 | Sell | 2.04K | $53K | 2026-06-22 | 2026-06-24 |
HOMCY CHARLES J Director · Stock Option (Right to Buy) · 2026-06-08 | Grant | 18K | $0 | 2026-06-08 | 2026-06-10 |
Hoppenot Herve Director · Stock Option (Right to Buy) · 2026-06-08 | Grant | 18K | $0 | 2026-06-08 | 2026-06-10 |
SPIEGELMAN DANIEL K Director · Stock Option (Right to Buy) · 2026-06-08 | Grant | 18K | $0 | 2026-06-08 | 2026-06-10 |
SEC filings
EDGAR filings in MAZE · 7 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.